These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 10170205)
41. Role of clinical, patient-reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey. Haslé-Pham E; Arnould B; Späth HM; Follet A; Duru G; Marquis P; Health Policy; 2005 Feb; 71(2):205-12. PubMed ID: 15607382 [TBL] [Abstract][Full Text] [Related]
42. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
43. Comparison analysis. Critics questioning design of effectiveness studies. DoBias M Mod Healthc; 2009 Feb; 39(8):10. PubMed ID: 19274822 [No Abstract] [Full Text] [Related]
45. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Garrison LP; Towse A; Bresnahan BW Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745 [TBL] [Abstract][Full Text] [Related]
46. Eliminating the printed formulary: a cost-effective alternative. Kienle PC Hosp Pharm; 1990 Jun; 25(6):534-7. PubMed ID: 10104829 [TBL] [Abstract][Full Text] [Related]
47. P & T Committee interview: strategies to ensure an effective formulary system. Riff L; Hutchinson R Hosp Formul; 1988 Nov; 23(11):901-4, 907-8. PubMed ID: 10290754 [TBL] [Abstract][Full Text] [Related]
48. Formulary management in an integrated health care system. Beis SJ; Anandan JV Pharm Pract Manag Q; 1999 Jan; 18(4):43-9. PubMed ID: 10339067 [No Abstract] [Full Text] [Related]
49. P & T Committee formulary requests: criteria for admission. Weintraub M; Guttmacher L Hosp Formul; 1984 Oct; 19(10):975-7, 980. PubMed ID: 10268315 [TBL] [Abstract][Full Text] [Related]
50. Antineoplastic agents: comparing off-label uses among authoritative drug compendia. Thompson DF; Keefe CC Hosp Formul; 1993 Jul; 28(7):641-2, 647. PubMed ID: 10127046 [TBL] [Abstract][Full Text] [Related]
51. Stoning a dead bird: advertising limits on approved new drugs. Strobos J Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018 [No Abstract] [Full Text] [Related]
52. Adding an expensive drug to the formulary. Uretsky SD; Kaatz BL Am J Hosp Pharm; 1993 Aug; 50(8):1667; discussion 1667-71. PubMed ID: 8368221 [No Abstract] [Full Text] [Related]
54. Assessing potential risks and evaluating expected benefits. Shaya FT; Gu A Manag Care Interface; 2005 May; 18(5):27-30. PubMed ID: 15941187 [TBL] [Abstract][Full Text] [Related]
55. Application of cost-effectiveness analysis to multiple products: a practical guide. Bala MV; Zarkin GA Am J Manag Care; 2002 Mar; 8(3):211-8. PubMed ID: 11915971 [TBL] [Abstract][Full Text] [Related]
56. Providing health economic data to managed care. Navarro RP Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588 [No Abstract] [Full Text] [Related]
57. Healthcare must be wary of Red Queen Principle. Tong DA Mod Healthc; 1996 Nov; 26(46):88. PubMed ID: 10163082 [No Abstract] [Full Text] [Related]
58. Evidence-based decision making: using submission guidelines to inform formulary approvals. Anis AH Am J Manag Care; 1999 Mar; 5(3):356-8. PubMed ID: 10351031 [No Abstract] [Full Text] [Related]
59. Economic analysis in healthcare decisions. Tunis SR Am J Manag Care; 2004 May; 10(5):301-4. PubMed ID: 15152698 [No Abstract] [Full Text] [Related]
60. Variety of factors influence health plan selection. Capitation Manag Rep; 1997 Oct; 4(10):164-5. PubMed ID: 10175786 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]